Strides Pharma Science has executed definitive agreements with funds advised by ICP?III Investment Advisors (ICP) to provide growth capital and focused attention to its Consumer Healthcare Business (CHC).
ICP would provide the business with a $20 million capital for growth. The CHC business comprises of key brands including JointFlex, Pediacare, NiteThru and NixIt sold across key regulated and emerging markets. The business had revenues of $6.4 million for FY18.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
